Iterum Therapeutics Regains Nasdaq Compliance
Iterum Therapeutics Regains Nasdaq Compliance
Iterum Therapeutics plc (NASDAQ:ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced receipt of written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the Company that its deficiency under Listing Rule 5550(b) has been cured and that the Company is in compliance with applicable continued listing requirements.
Iterum Therapeutics plc（納斯達克股票代碼：ITRM）（以下簡稱 「公司」）是一家專注於提供下一代口服和靜脈抗生素以治療社區和醫院環境中耐多藥病原體引起的感染的公司。該公司今天宣佈收到了納斯達克股票市場有限責任公司上市資格工作人員的書面通知，通知該公司根據上市規則5550（b），其缺陷已得到治癒，該公司遵守了適用的持續上市要求。
Based on the foregoing, the previously scheduled Nasdaq hearing before the Hearings Panel on November 21, has been cancelled. The Company will continue to be traded on The Nasdaq Capital Market.
基於上述情況，原定於11月21日在納斯達克舉行的聽證會小組的聽證會已取消。該公司將繼續在納斯達克資本市場上交易。
